» Articles » PMID: 36776841

Exposed Seronegative: Cellular Immune Responses to SARS-CoV-2 in the Absence of Seroconversion

Overview
Journal Front Immunol
Date 2023 Feb 13
PMID 36776841
Authors
Affiliations
Soon will be listed here.
Abstract

The factors determining whether infection will occur following exposure to SARS-CoV-2 remain elusive. Certain SARS-CoV-2-exposed individuals mount a specific T-cell response but fail to seroconvert, representing a population that may provide further clarity on the nature of infection susceptibility and correlates of protection against SARS-CoV-2. Exposed seronegative individuals have been reported in patients exposed to the blood-borne pathogens Human Immunodeficiency virus and Hepatitis C virus and the sexually transmitted viruses Hepatitis B virus and Herpes Simplex virus. By comparing the quality of seronegative T-cell responses to SARS-CoV-2 with seronegative cellular immunity to these highly divergent viruses, common patterns emerge that offer insights on the role of cellular immunity against infection. For both SARS-CoV-2 and Hepatitis C, T-cell responses in exposed seronegatives are consistently higher than in unexposed individuals, but lower than in infected, seropositive patients. Durability of T-cell responses to Hepatitis C is dependent upon repeated exposure to antigen - single exposures do not generate long-lived memory T-cells. Finally, exposure to SARS-CoV-2 induces varying degrees of immune activation, suggesting that exposed seronegative individuals represent points on a spectrum rather than a discrete group. Together, these findings paint a complex landscape of the nature of infection but provide clues as to what may be protective early on in SARS-CoV-2 disease course. Further research on this phenomenon, particularly through cohort studies, is warranted.

Citing Articles

Exploring the Relationship Between Humoral and Cellular T Cell Responses Against SARS-CoV-2 in Exposed Individuals From Emilia Romagna Region and COVID-19 Severity.

Mazzotti L, Borges de Souza P, Azzali I, Angeli D, Nanni O, Sambri V HLA. 2025; 105(1):e70011.

PMID: 39807702 PMC: 11731316. DOI: 10.1111/tan.70011.


Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection.

Ahmed M, Einhauser S, Peiter C, Senninger A, Baranov O, Eser T iScience. 2024; 27(6):110138.

PMID: 38974469 PMC: 11225850. DOI: 10.1016/j.isci.2024.110138.


Detection of SARS-CoV-2-Specific Secretory IgA and Neutralizing Antibodies in the Nasal Secretions of Exposed Seronegative Individuals.

Chwa J, Kim M, Lee Y, Cheng W, Shin Y, Jumarang J Viruses. 2024; 16(6).

PMID: 38932145 PMC: 11209246. DOI: 10.3390/v16060852.


Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study.

Hvidt A, Guo H, Andersen R, Lende S, Vibholm L, Sogaard O BMC Immunol. 2023; 24(1):45.

PMID: 37974069 PMC: 10652616. DOI: 10.1186/s12865-023-00583-y.


Cytometry profiling of recall responses to in previously naturally exposed individuals reveals long-term changes in both adaptive and innate immune cellular compartments.

Raju Paul S, Scholzen A, Reeves P, Shepard R, Hess J, Dzeng R Front Immunol. 2023; 14:1249581.

PMID: 37885896 PMC: 10598782. DOI: 10.3389/fimmu.2023.1249581.


References
1.
Provine N, Klenerman P . MAIT Cells in Health and Disease. Annu Rev Immunol. 2020; 38:203-228. DOI: 10.1146/annurev-immunol-080719-015428. View

2.
Ranki A, Mattinen S, Yarchoan R, Broder S, Ghrayeb J, Lahdevirta J . T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. AIDS. 1989; 3(2):63-9. DOI: 10.1097/00002030-198902000-00002. View

3.
Kundu R, Narean J, Wang L, Fenn J, Pillay T, Fernandez N . Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat Commun. 2022; 13(1):80. PMC: 8748880. DOI: 10.1038/s41467-021-27674-x. View

4.
Clerici M, Levin J, Kessler H, Harris A, Berzofsky J, Landay A . HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA. 1994; 271(1):42-6. View

5.
Buckland M, Galloway J, Nic Fhogartaigh C, Meredith L, Provine N, Bloor S . Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nat Commun. 2020; 11(1):6385. PMC: 7736571. DOI: 10.1038/s41467-020-19761-2. View